BackMoleculin Biotech Overview

Moleculin Biotech Inventory

Track Moleculin Biotech's inventory ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Inventory
$0.00

Peer trimmed avg / median

Loading

Moleculin Biotech Inventory History

Loading

Moleculin Biotech vs. peers: Inventory Comparison

Loading

Moleculin Biotech Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Moleculin Biotech (MBRX) FAQ

Moleculin Biotech (MBRX) currently reports a inventory of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Moleculin Biotech's inventory history and peer comparisons.

Moleculin Biotech's inventory changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Moleculin Biotech reported $0 in inventory as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current inventory of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Moleculin Biotech, and consider following MBRX for alerts when major investors trade the stock.

Moleculin Biotech is classified in the Healthcare sector. On inventory, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MBRX with unrelated industries.